481 related articles for article (PubMed ID: 12660333)
1. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Hansen BV; Parving HH
Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
[TBL] [Abstract][Full Text] [Related]
4. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Rossing K; Christensen PK; Jensen BR; Parving HH
Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
7. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
8. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
9. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Stergiou GS; Makris T; Papavasiliou M; Efstathiou S; Manolis A
J Hypertens; 2005 Apr; 23(4):883-9. PubMed ID: 15775795
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
12. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Wilkinson-Berka JL; Gibbs NJ; Cooper ME; Skinner SL; Kelly DJ
Nephrol Dial Transplant; 2001 Jul; 16(7):1343-9. PubMed ID: 11427623
[TBL] [Abstract][Full Text] [Related]
14. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Viberti G; Wheeldon NM;
Circulation; 2002 Aug; 106(6):672-8. PubMed ID: 12163426
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
19. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
[TBL] [Abstract][Full Text] [Related]
20. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Slagman MC; Waanders F; Hemmelder MH; Woittiez AJ; Janssen WM; Lambers Heerspink HJ; Navis G; Laverman GD;
BMJ; 2011 Jul; 343():d4366. PubMed ID: 21791491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
